Palopegteriparatide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), HAS (France) and NYE METODER (Norway) recommended or restricted palopegteriparatide, while DMC (Denmark) and PBAC (Australia) did not recommend it.
The record spans 2.2 years, opening at G-BA (Germany) on 20 Jun 2024 and running to 20 Sep 2026.
CIPM (Spain) changed its position: not recommended on 26 Feb 2025, recommended by 21 May 2025, after a resubmission.
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand), AWMSG (Wales) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 11 of 11 records date from 2023 or later.
Against its own class, palopegteriparatide is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class H05A average 77%.
2 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
G-BA (Germany) was first to assess palopegteriparatide, on 20 Jun 2024; NYE METODER (Norway) did not open a file until 20 Sep 2026 — a moderate spread of 2.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 11 dated records fall in 2025 alone.
3 of the 8 agencies here assessed palopegteriparatide more than once, CHUIKYO (Japan) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for palopegteriparatide.
The full ledger for palopegteriparatide reads 4 not recommended, 3 recommended, 2 no benefit and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AIFA (Italy) | 1 Apr 2026 | Yorvipath è una terapia sostitutiva dell'ormone paratiroideo (PTH) indicata per il trattamento di adulti con ipoparatiro… | innovative status not granted · reimbursed class A | source |
| DMC (Denmark) | 25 Mar 2026 | Palopegteriparatid er et parathyroideahormon (PTH) til substitu-tionsbehandling, som er indiceret til behandling af voks… | Ikke anbefalet | source |
| CHUIKYO (Japan) | 22 Oct 2025 | ヨビパス皮下注１６８μｇペン | listed on the NHI price list · 58 days after PMDA approval | source |
| PBAC (Australia) | 2025 | Chronic hypoparathyroidism | Not recommended | source |
| CIPM (Spain) | 21 May 2025 | Indicación terapéutica autorizada: Yorvipath es un tratamiento sustitutivo de la hormona paratiroidea (PTH) indicado par… | financed by the SNS, on appeal · art. 92 a, c | source |
6 further decisions for palopegteriparatide, across 6 agencies, are not shown here. They include the most recent record on file, 20 Sep 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- teriparatide — same ATC class H05A — Calcium homeostasis
- abaloparatide — same ATC class H05A — Calcium homeostasis
- guselkumab — also decided by NYE METODER in 2026Q3
- ponatinib — also decided by NYE METODER in 2026Q3
- bimekizumab — also decided by NYE METODER in 2026Q3
- nivolumab — also decided by NYE METODER in 2026Q3
Coverage: 11 decisions for palopegteriparatide from 8 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class H05A — Calcium homeostasis. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.